International journal of clinical and experimental medicine · 2015
Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yi-Ping, Tang Dong-Xin
Аннотация
OBJECTIVE: To investigate the expression of Yes-associated protein (YAP) in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.
METHODS: A total of 95 patients receiving surgery due to liver cancer were recruited.
RESULTS: In 95 liver cancers, YAP expression was significantly higher than that in adjacent normal tissues. In addition, of liver cancers, 14.7% was negative for YAP (14/95), 29.5% (28/95) weakly positive, 21.1% (20/95) positive and 34.7% (33/95) strong positive, and low expression and high expression were observed in 44.2% (42/95) and 55.8% (53/95) of liver cancers, respectively. Of adjacent normal tissues, 13.7% (13/95) were negative or weakly positive for YAP. The mean survival time of patients with high YAP expression was significantly longer than that of patients with low YAP expression (Log-rank = 9.206, P < 0.01). Univariate analysis showed portal vein thrombosis (P < 0.01), metastasis (P < 0.01), American Joint Committee on Cancer Staging (AJCC) stage (P < 0.01), alpha fetoprotein (AFP) (P < 0.01) and high YAP expression (P < 0.01) were factors affecting the overall survival of liver cancer patients. However, multivariate analysis showed metastasis (P < 0.01) and high YAP expression (P < 0.01) were independent risk factors of overall survival of liver cancer patients.
CONCLUSION: YAP expression increases significantly in liver cancer and it may be involved in the occurrence and development of liver cancer. YAP expression is an independent risk factor affecting the overall survival of liver cancer patients.
METHODS: A total of 95 patients receiving surgery due to liver cancer were recruited.
RESULTS: In 95 liver cancers, YAP expression was significantly higher than that in adjacent normal tissues. In addition, of liver cancers, 14.7% was negative for YAP (14/95), 29.5% (28/95) weakly positive, 21.1% (20/95) positive and 34.7% (33/95) strong positive, and low expression and high expression were observed in 44.2% (42/95) and 55.8% (53/95) of liver cancers, respectively. Of adjacent normal tissues, 13.7% (13/95) were negative or weakly positive for YAP. The mean survival time of patients with high YAP expression was significantly longer than that of patients with low YAP expression (Log-rank = 9.206, P < 0.01). Univariate analysis showed portal vein thrombosis (P < 0.01), metastasis (P < 0.01), American Joint Committee on Cancer Staging (AJCC) stage (P < 0.01), alpha fetoprotein (AFP) (P < 0.01) and high YAP expression (P < 0.01) were factors affecting the overall survival of liver cancer patients. However, multivariate analysis showed metastasis (P < 0.01) and high YAP expression (P < 0.01) were independent risk factors of overall survival of liver cancer patients.
CONCLUSION: YAP expression increases significantly in liver cancer and it may be involved in the occurrence and development of liver cancer. YAP expression is an independent risk factor affecting the overall survival of liver cancer patients.